Site Networks vs. Independents: The Consolidation Question

The site landscape is consolidating. Network-owned and private-equity-backed site organizations have grown from curiosity to major force, and sponsors increasingly place multi-site awards through central feasibility teams. Independent sites feel the squeeze — and have more options than the gloom suggests.

What networks actually offer sponsors

Central contracting, standardized processes, pooled patient databases, and single-signature multi-site awards. For sponsors under timeline pressure, one negotiation covering fifteen sites is genuinely valuable — that's the consolidation engine, more than any claim about site quality.

Where independents still win

Specialization depth. The independent site that owns its region's referral network in hepatology or has the metro's largest lupus registry offers something no network's breadth substitutes for.

Community roots. Long-tenured local sites hold trust relationships — with physicians, community organizations, and past participants — that acquisition can't transfer and centralization tends to erode.

Agility. Decision-making that happens in one room: startup documents turned around in days, budgets negotiated by the person who'll run the study, protocol questions answered by the PI who'll see the patients.

Strategic options short of selling

Alliance models. Independent site consortia share feasibility pipelines and present sponsors a multi-site front while preserving ownership — the network advantage without the acquisition.

Data-driven positioning. Sponsors centralize partly because site claims are unverifiable. Independents with clean performance metrics — enrollment against commitment, startup timelines, retention rates — puncture that rationale one study at a time.

Deliberate niching. Being the obvious site for a therapeutic area in a region beats being a generalist competing on price against network scale.

Consolidation is real, but it isn't destiny. The independents that thrive will be the ones that choose a strategy — depth, alliance, or excellence made legible — rather than defaulting to business as usual with fewer studies.